Send me real-time posts from this site at my email

Trading List: Feb. 2 - Updates & Analyst Actions - KPTI, OMER

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.


Karyopharm price target lowered to $26 from $31 at Barclays

Barclays analyst Peter Lawson lowered the firm's price target on Karyopharm Therapeutics to $26 from $31 and keeps an Overweight rating on the shares. The analyst is encouraged with the positive CHMP opinion for selinexor but updated his model to reflect the "negative" preannouncement.

"Our Take:  KPTI is on our favorites list due to its potential and active options available for trading. Selling puts to build a position here is a good idea. Also some buy/writes might pay off. We think the reduction in price target is due to this stock being stuck in a trading range for sometime."


Omeros initiated with a Buy at UBS

UBS analyst Colin Bristow initiated coverage of Omeros with a Buy rating and $25 price target. The company's Narsoplimab is the "central tenet" of the bullish thesis as the only drug to target the lectin pathway, which should allow for differentiation vs. other complement inhibitors, the analyst tells investors in a research note. Bristow adds that the market is underappreciating this asset, specifically its potential in IgA nephropathy.

"Our Take:  On our favorites list with good potential. Had recently moved up a bit and it maybe better to wait if initiating a new position. If already owned this is a good time to sell a few covered calls to lock in some of the gains. Also maybe buy an upside call incase of a major breakout. Depends on your on risk tolerance."


$OMER, Omeros Corporation / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue